Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00030459
Other study ID # BTS-MESO-1
Secondary ID CDR0000069167MRC
Status Active, not recruiting
Phase Phase 2
First received February 14, 2002
Last updated August 6, 2013
Start date November 2000

Study information

Verified date May 2003
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Palliative therapy may help patients with advanced cancer live more comfortably. It is not yet known if palliative therapy is more effective with or without chemotherapy in treating patients who have malignant mesothelioma.

PURPOSE: Randomized phase II trial to compare the effectiveness of palliative therapy with or without different chemotherapy regimens in treating patients who have malignant mesothelioma.


Description:

OBJECTIVES:

- Determine the feasibility of palliative therapy alone versus palliative therapy with mitomycin, vinblastine, and cisplatin versus palliative therapy with vinorelbine in patients with malignant mesothelioma.

- Determine the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of three treatment arms.

- Arm I: Patients receive palliative therapy alone comprising non-chemotherapeutic therapy (e.g., radiotherapy, painkillers, steroids, relaxants, and special pain relief techniques).

- Arm II: Patients receive palliative therapy as in arm I and chemotherapy comprising mitomycin IV (courses 1, 2, and 4 only), vinblastine IV, and cisplatin IV over 4 hours on day 1. Chemotherapy repeats every 21 days for a total of 4 courses.

- Arm III: Patients receive palliative therapy as in arm I and chemotherapy comprising vinorelbine IV over 5 minutes once weekly on weeks 1-6 and 9-14.

Quality of life is assessed at baseline for all patients; at weeks 3, 6, 9, and 12 for arm I; at weeks 4, 7, 10, and 13 for arm II; at weeks 3, 6, 10, and 13 for arm III; at weeks 21 and 29, and then every 8 weeks thereafter for all patients.

Patients are followed every 8 weeks.

PROJECTED ACCRUAL: A total of 60 patients (20 per treatment arm) will be accrued for this study within 1 year.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility DISEASE CHARACTERISTICS:

- Immunohistochemically or cytologically confirmed malignant mesothelioma

- Epithelial and other histological types

- Symptomatic pleural effusion allowed if treated and controlled by drainage, pleurodesis, or pleurectomy

- Prior surgical resection allowed if stable or progressive disease by 2 CT scan measurements at least 6 weeks apart

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- WHO 0-2

Life expectancy:

- Not specified

Hematopoietic:

- WBC greater than 3,000/mm3

- Neutrophil count greater than 1,500/mm3

- Platelet count greater than 100,000/mm3

Hepatic:

- Not specified

Renal:

- Not specified

Other:

- Considered medically fit to receive chemotherapy

- No other disease or prior malignancy that would preclude study

- No clinical evidence of infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy for mesothelioma

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- See Disease Characteristics

Study Design

Allocation: Randomized, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
cisplatin

mitomycin C

vinblastine sulfate

vinorelbine tartrate


Locations

Country Name City State
United Kingdom Aberdeen Royal Infirmary Aberdeen Scotland
United Kingdom Dorothy House Foundation Bradford-Onavon
United Kingdom St. Peters Hospital Chertsey Surrey
United Kingdom Stobhill General Hospital Glasgow Scotland
United Kingdom Princess Royal Hospital Hull England
United Kingdom Leeds Teaching Hospital Trust Leeds England
United Kingdom Medical Research Council Clinical Trials Unit London England
United Kingdom Saint Bartholomew's Hospital London England
United Kingdom Royal Marsden Hospital Sutton England

Sponsors (2)

Lead Sponsor Collaborator
British Thoracic Society Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

See also
  Status Clinical Trial Phase
Recruiting NCT06057935 - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Phase 2
Completed NCT00821860 - Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Phase 3
Completed NCT00075699 - Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Phase 3
Completed NCT00004033 - Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT03678350 - Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery Phase 1
Recruiting NCT02580747 - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso Phase 1
Completed NCT00398138 - Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Phase 1
Completed NCT00019825 - Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura Phase 1
Terminated NCT00898547 - Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Completed NCT00004183 - Capecitabine in Treating Patients With Malignant Mesothelioma Phase 2
Completed NCT00005636 - Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Phase 3
Completed NCT00004920 - Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Phase 3
Completed NCT00004254 - Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed Phase 2
Completed NCT00334594 - Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT01291420 - Dendritic Cell Vaccination for Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT03852823 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1
Active, not recruiting NCT01649024 - A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Phase 2
Completed NCT00513877 - Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT00372840 - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer N/A
Active, not recruiting NCT00253409 - Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery N/A